Researchers attribute the drop to an intensely competitive market for medical technology.
The following categories of devices saw price declines:
• Drug-eluting stents — 34 percent
• Artificial hips — 23 percent
• Artificial knees — 17 percent
• Implantable defibrillators — 24 percent
• Bare metal stents — 27 percent
More Articles on Devices:
7 Key Notes on Spine & Orthopedic Device Companies
6 New Spine, Orthopedic Device Launches & Approvals
Dr. William Geissler Implants First Integra LifeSciences’ Titan Reverse Shoulder System
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
